Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Thalidomide
Drug ID BADD_D02192
Description A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Indications and Usage For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Marketing Status approved; investigational; withdrawn
ATC Code L04AX02
DrugBank ID DB01041
KEGG ID D00754
MeSH ID D013792
PubChem ID 5426
TTD Drug ID D0U7GK
NDC Product Code 17205-205; 59572-215; 68554-0011; 82991-205; 59572-220; 17337-0301; 59572-210; 59572-205; 63818-0424
UNII 4Z8R6ORS6L
Synonyms Thalidomide | Sedoval | Thalomid
Chemical Information
Molecular Formula C13H10N2O4
CAS Registry Number 50-35-1
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Periodontitis11.01.04.012; 07.09.01.002--Not Available
Peripheral motor neuropathy17.09.03.004--
Peripheral sensory neuropathy17.09.03.0050.000482%
Peripheral vascular disorder24.03.01.0030.000241%Not Available
Peritonitis07.19.05.004; 11.01.07.007--
Peroneal nerve palsy17.09.02.003--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Phaeochromocytoma16.24.02.004; 05.01.04.0040.000241%Not Available
Pharyngitis07.05.07.004; 22.07.03.004; 11.01.13.003--
Photosensitivity reaction23.03.09.003--
Plasma cell leukaemia16.23.02.003; 01.14.02.0030.000723%Not Available
Plasma cell myeloma16.23.02.004; 01.14.02.0040.038723%Not Available
Plasmacytoma16.23.02.002; 01.14.02.0020.001133%Not Available
Platelet count decreased13.01.04.001--
Platelet disorder01.08.03.0010.000530%Not Available
Pleural effusion22.05.02.002--
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pneumothorax22.05.02.0030.000362%
Pollakiuria20.02.02.007--
Polyneuropathy17.09.03.0120.000772%Not Available
Portal vein thrombosis24.01.03.003; 09.01.06.0070.000241%
Prostate cancer metastatic21.04.02.004; 16.25.01.0020.000241%Not Available
Proteinuria20.02.01.011--
Prothrombin time abnormal13.01.02.017--Not Available
Pruritus23.03.12.001--
Psoriasis10.02.01.036; 23.03.14.002--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.0010.005353%Not Available
Pulmonary fibrosis22.01.02.0060.000723%
Pulmonary hypertension22.06.01.001; 24.08.03.0020.001085%
Pulmonary oedema22.01.03.003; 02.05.02.0030.002459%
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene